MYOCARDIAL SILENT INFARCTIONS AND FIBROSIS IN FAMILIAL HYPERCHOLESTEROLEMIA (CHOLCOEUR)

Inclusion criteria: For patients with heterozygous form of familial hypercholesterolemia: * Aged between 40 and 60 years * With an identified genetic mutation (LDL-R, ApoB, PCSK9) * Asymptomatic, * With no EKG sign of ischemia * No personal history of coronary heart disease. * Treated or untreated by lipid lowering treatment * High cardiovascular risk identified by 1 of the following criteria: 1\. Current smoking (1 cigarette a day) 2 Family history of very premature onset CHD: first- or second-degree male relative onset before age 45, first- or second-degree female relative onset before age 55 3.Two or more cardiovascular risk factors among this list: increasing age (men \> 30, women \> 40 years of age), LDL-C \> 250 mg/dL, male sex, family history of premature onset CHD, first-degree male relative onset before age 55, first-degree female relative onset before age 65, metabolic syndrome, HDL-C \< 40 mg/dL, hypertension (BP \> 140/or \> 90 mmHg or drug treatment), Lp (a) ≥ 50 mg/dL, tendon xanthoma For control subjects: * Aged between 40 and 60 years * With a normal lipid profile (LDL-C \< 1.6g/L HDL-C \> 0,45g/L and TG \< 4g/L) and untreated by any lipid lowering therapies * Asymptomatic, * With EKG showing normal sinus rhythm , no sign of ischemia nor Left Bundle Branch Block * No personal history of coronary heart disease. * Control subjects will be matched for age/gender/smoking status and blood pressure Exclusion criteria: * Non-affiliation to a healthcare system * Consent refusal * Contra-indication to MRI or to gadolinium injection. * Claustrophobia, metallic devices, pacemaker, mechanical valve implanted before 1985, pregnancy, nursing * Renal failure * Technical contra-indication: patient diameter \> 70 cm weight \> 250 kg * Personal history of cardiovascular disease and myocardial infarction * Diabetes mellitus * Uncontrolled hypertension * TG \< 4 g/L * Previous use of an Amgen product in the past 12 months